BWX Technologies Reports Third Quarter 2024 Results
BWX Technologies, Inc. reported third quarter 2024 results.
BWXT selected for nuclear fuel deconversion award by U.S. Department of Energy
BWX Technologies, Inc. (NYSE: BWXT) today announced that its Nuclear Fuel Services, Inc. (NFS) subsidiary was selected by the U.S. Department of Energy (DOE) as one of the successful bidders for High-Assay Low-Enriched Uranium (HALEU) deconversion services to support the civil advanced reactor marketplace.
BWXT Names Gary D. Camper President of Nuclear Operations Group Subsidiary
(LYNCHBURG, Va. – Sept. 3, 2024) – BWX Technologies, Inc. (NYSE: BWXT) announced today that Gary D. Camper has been appointed president of BWXT Nuclear Operations Group, Inc. (NOG) effective Sept. 1, 2024.
BWXT Awarded Contract to Develop Pilot Plant Solution for Domestic Uranium Enrichment
(LYNCHBURG, Va. – August 26, 2024) – BWX Technologies, Inc. (NYSE: BWXT) today announced a contract from the National Nuclear Security Administration (NNSA) to complete a yearlong engineering study to evaluate options for the deployment of a centrifuge pilot plant that would establish a domestic uranium enrichment capability for national security purposes.
BWXT Names Vittorio Puppo President of Medical Business
BWX Technologies, Inc. (NYSE: BWXT) has appointed Vittorio Puppo as president of BWXT Medical Ltd., effective August 12, 2024. In his new role, Puppo will focus on advancing the business’ mission to deliver high-quality nuclear medical products and solutions that improve patient outcomes worldwide.
BWX Technologies Reports Second Quarter 2024 Results
LYNCHBURG, Va.--(BUSINESS WIRE)--BWX Technologies, Inc. (NYSE: BWXT) ("BWXT", "we", "us" or the "Company") reported second quarter 2024 results. A reconciliation of non-GAAP results are detailed in Exhibit 1.
BWXT Medical and NorthStar Medical Radioisotopes Sign Supply Agreement Supporting Actinium-225 Production
BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT) and NorthStar Medical Radioisotopes, LLC (NorthStar) today announced that they have signed a Master Services Agreement (MSA), which will facilitate the production of actinium-225 (Ac-225), a critical medical isotope used to kill cancer cells while minimizing the impact to healthy tissues.
BWXT Medical Submits Drug Master File for Actinium-225 API to U.S. Food and Drug Administration
BWXT Medical Ltd. has submitted a Drug Master File (DMF) to the U.S. Drug and Food Administration (FDA) for No Carrier Added (n.c.a.) Actinium-225 (Ac-225) Active Pharmaceutical Ingredient.
BWXT Named First Member of GE Vernova Nuclear’s Small Modular Reactor Supplier Group
BWXT Canada Ltd., a subsidiary of BWX Technologies, Inc. has been selected as the first qualified supply chain company to join the GE Vernova nuclear business’ supplier group that will advance the global deployment of the BWRX-300 small modular reactor (SMR).